Highlights Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
7.71 ^USD	+0.92%		-6.55%	+14.22%

May. 20	Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target	MT
May. 14	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal	May. 13	DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment	May. 13	MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug	May. 13	MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal	May. 13	DJ
Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy in The Lancet Neurology	May. 08	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Fulcrum Therapeutics Announces Lifting of Clinical Hold on Potential Sickle-Cell Disease Treatment	23-08-22	MT
Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease	23-08-22	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023	23-08-03	CI
Fulcrum Therapeutics Enters Exclusive License Agreement With CAMP4 Therapeutics to Advance Rare Blood Disorder Therapy	23-07-10	MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Fulcrum Therapeutics Q4 Loss Narrows, Revenue Falls	23-03-09	MT
FULCRUM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-09	AQ
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Highlights

Filters